Benjamin Hébraud
Centre Hospitalier Universitaire de Toulouse(FR)Institut universitaire du cancer de Toulouse Oncopole(FR)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, GDF15 and Related Biomarkers, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Signaling Pathways in Disease
Most-Cited Works
- → Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome(2014)263 cited
- → Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?(2013)204 cited
- → Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults(2018)133 cited
- → Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA(2022)120 cited
- → Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells(2019)103 cited
- → Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients(2013)102 cited